Pharmaceuticals News and Research

RSS

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has completed enrollment in the first of two dose cohorts in its Phase 1 clinical trial of PV-10 for liver cancer, and that the therapy was very well tolerated by all three subjects treated, with substantial evidence of efficacy.

15 Sep 2010

$Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy$

Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy

Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

15 Sep 2010

Stroke risk with common pain killers dismissed by manufacturer

An eight-year Danish study, which involved more than 2.5 million healthy Danes found there was a higher risk of stroke for those taking high doses of ibuprofen, which is in the painkiller Nurofen. The manufacturers of Nurofen, Reckitt Benckiser, have dismissed these reports. The spokesperson for the company said, “it is important to note that the conclusions drawn by the study authors are based on high doses of ibuprofen…The results of this study should not be confused with non-prescription low doses of NSAIDs, such as ibuprofen, which are available over-the-counter and used by millions of people around the world, for short periods of time, every day.”

14 Sep 2010

Pepscan, Tibotec sign Research and License Agreement

Pepscan Therapeutics, the Netherlands based biotechnology firm focusing on protein mimicry technology for the generation of novel therapeutics, today announced that it has signed a Research and License Agreement with Tibotec Pharmaceuticals, Ireland. Under the agreement Pepscan using its CLIPS technology will work with Tibotec to develop novel therapeutic peptides against an undisclosed target.

14 Sep 2010

UBM Live anticipates CPhI Worldwide attendance to exceed 25,000

Leading events organiser UBM Live today announced that it expects the attendance for CPhI Worldwide, the annual flagship tradeshow for pharma ingredients, now in its 21st year and the year being held in Paris, to exceed the 25,000 seen at last year's event, held in Madrid.

14 Sep 2010

Life Technologies finalizes cell line license agreement for recombinant protein production

Life Technologies Corporation today announced that it has finalized cell line license agreements with a number of companies to provide rights to Life Technologies' proprietary CHO (Chinese hamster ovary) cell lines for the production of recombinant proteins used as therapeutic agents and vaccines.

14 Sep 2010

Enrollment in Derma Sciences DSC127 Phase 2 trial in diabetic foot ulcer healing to conclude September end

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that patient screening in its DSC127 Phase 2 trial in diabetic foot ulcer healing will be completed tomorrow, and that enrollment in the trial will conclude on September 30. This randomized, double-blind, placebo controlled study of up to 75 patients will look at the percentage of diabetic ulcers completely healed over a 12-week period, among other outcomes.

14 Sep 2010

AstraZeneca Chief Scientist shares enthusiasm for collaborative clinical research

The pharmaceutical industry must ensure an improved record of delivery by providing high quality, cost effective solutions to well defined unmet needs. This can be achieved through strategic collaborations that strengthen disease knowledge and provide improved tools to strengthen therapeutic target validation and to monitor therapeutic efficacy, says Andy Dray, Chief Scientist at AstraZeneca.

14 Sep 2010

Absence of clean, sanitary drinking water a global concern

One of the biggest concerns facing Americans and people worldwide today is the absence of clean, sanitary drinking water. Over the past few years people have begun to wake up to the fact that their tap water isn't as clean as they originally thought; the discovery has been made that a large portion of drinking water in the United States is laced with pharmaceuticals and chemicals.

14 Sep 2010

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of diabetes mellitus type II.

14 Sep 2010

SAMHSA to unveil results of 2009 National Survey on Drug Use and Health

The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2009) National Survey on Drug Use and Health (NSDUH) at a press conference on Thursday, September 16. The annual survey is the largest of its kind, and is the government's primary vehicle for determining how many persons are abusing illegal drugs, pharmaceuticals, alcohol and tobacco.

14 Sep 2010

AMCP supports legislation to prohibit financial agreements for delaying marketing of lower-cost generic drugs

The Academy of Managed Care Pharmacy (AMCP) supports the inclusion of legislative language similar to S. 369 — the Preserve Access to Affordable Generics Act — in appropriations legislation now under consideration by the Senate. S. 369 would prohibit financial agreements between brand-name and generic pharmaceutical manufacturers to delay the marketing of lower-cost generic drugs.

14 Sep 2010

Pernix completes Macoven acquisition

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company primarily focused on the pediatric market, today announced the acquisition of 100% of the outstanding membership interest in Macoven Pharmaceuticals, L.L.C. for approximately $2.2 million (which includes inventory of approximately $1.2 million), its entry into a $10 million credit facility with Regions Bank and the repurchase of 2,000,000 shares of its common stock from one of its employees in a privately negotiated transaction.

14 Sep 2010

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Progenics Pharmaceuticals, Inc. today presented preclinical findings for its humanized monoclonal antibodies against the disease-causing toxins produced by the bacterium Clostridium difficile.

14 Sep 2010

$Bisphosphonates drug may lead to atypical femur fractures in osteoporosis patients: Report$

Bisphosphonates drug may lead to atypical femur fractures in osteoporosis patients: Report

A widely prescribed class of drugs is highly effective in reducing common bone fractures in people with osteoporosis, but an expert panel announced today that these same drugs - when used long term - may be related to unusual but serious fractures of the thigh bone.

14 Sep 2010

Structural component inside neurons dances when connections are strengthened

Scientists at Emory University School of Medicine have uncovered how a structural component inside neurons performs two coordinated dance moves when the connections between neurons are strengthened.

14 Sep 2010

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for delafloxacin in four poster sessions at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

14 Sep 2010

Safety-minded physicians likely to adopt emerging brands in asthma treatment: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, identifies a segment of safety-minded physicians who are the most likely to rapidly adopt emerging brands with a novel mechanism of action when compared with other physician segments in the analysis.

14 Sep 2010

Neoprobe Corporation presents information on Lymphoseek at TERACHEM Symposium

Neoprobe Corporation a diversified developer of innovative oncology surgical and diagnostic products, today announced that Senior Vice President of Pharmaceutical Research and Clinical Development, Dr. Frederick O. Cope, presented information on the Company's lead pipeline initiative, Lymphoseek, at the International Symposium on Technetium and Other Radiometals in Chemistry and Medicine (TERACHEM), held September 8-11, 2010 in Bressanone (Bolzano), Italy.

14 Sep 2010

Momenta Pharmaceuticals receives patent for enoxaparin

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that on September 7, 2010 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,790,466, entitled "Evaluating Mixtures of Low Molecular Weight Heparins By Chain Profiles or Chain Mapping".

14 Sep 2010

Pharmaceuticals News and Research

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy

Stroke risk with common pain killers dismissed by manufacturer

Pepscan, Tibotec sign Research and License Agreement

UBM Live anticipates CPhI Worldwide attendance to exceed 25,000

Life Technologies finalizes cell line license agreement for recombinant protein production

Enrollment in Derma Sciences DSC127 Phase 2 trial in diabetic foot ulcer healing to conclude September end

AstraZeneca Chief Scientist shares enthusiasm for collaborative clinical research

Absence of clean, sanitary drinking water a global concern

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

SAMHSA to unveil results of 2009 National Survey on Drug Use and Health

AMCP supports legislation to prohibit financial agreements for delaying marketing of lower-cost generic drugs

Pernix completes Macoven acquisition

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Bisphosphonates drug may lead to atypical femur fractures in osteoporosis patients: Report

Structural component inside neurons dances when connections are strengthened

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Safety-minded physicians likely to adopt emerging brands in asthma treatment: Report

Neoprobe Corporation presents information on Lymphoseek at TERACHEM Symposium

Momenta Pharmaceuticals receives patent for enoxaparin

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence